Dr. Donald Poirier has been a professor at the Department of Molecular Medicine (Faculty of Medicine, Laval University, Québec, Qc) since July 1991 as well as a researcher at the CHU de Québec – Research Center (Québec, Qc). Since 2008, he has also been Director of the Organic Synthesis Service and Co-Director of the Analytical and Medicinal Chemistry Platform.

Professor Poirier received his basic training in organic chemistry (PhD from Laval University, 1980-1985) and subsequently specialized in medicinal chemistry and endocrinology (Postdoctoral studies at the CHUL-Research Center, 1986-1990, CRM fellowship) and more recently in solid phase synthesis of small molecules of therapeutic interest such as steroid derivatives. He is especially interested in the development of steroidogenic enzyme (17b-HSDs, steroid sulfatase, CYP1B1) inhibitors and antitumor agents for the treatment of different cancers (breast, prostate, ovary, pancreatic, and leukemia). As examples, he developed the first non-estrogenic irreversible steroidal inhibitor of 17β-HSD1 for the treatment of breast cancer and endometriosis. He also developed a family of aminosteroid derivatives that inhibited tumor growth in mice for different cancers (breast, ovary, pancreatic, and leukemia).

In addition to the synthesis of small molecules by classical chemistry, he succeeded by developing solid-phase syntheses of C18-steroid (estrane) derivatives as well as C19-steroid (androstane) derivatives that enabled the generation of model libraries of targeted therapeutic compounds. Thus, he developed a diethylsilylacetylenic linker that produces more stable compounds and a sulfamate linker that produces two classes (phenol and sulfamate) of relevant steroidal or nonsteroidal compounds according to cleavage conditions. He is also interested in additional aspects of organic chemistry (synthesis, new methodologies, NMR analysis, etc.) and medicinal chemistry (SAR, molecular modeling, biological assays, etc.). A particularity of his research group is that he is interested in several stages of the development of a new drug: conception, chemical synthesis, in vitro biological tests (enzymatic assays, cell proliferation, etc.) and in vivo (estrogenic activities and androgenic in female and male mice, plasma concentration, metabolic stability, xenografts of cancer cells, etc.).

Professor Poirier has published 220 scientific publications and is the holder of 11 patents and patent applications. He has also been involved in more than 450 oral and poster presentations, as well as conferences as invited speaker.

CHUL
2705, boulevard Laurier
T-4-50
Québec, Québec
Canada G1V 4G2
202 entries « 1 of 41 »

Sang X, Han H, Poirier D, Lin SX

Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: an underlying mechanism.

Journal Article

J Steroid Biochem Mol Biol, 2018, ISSN: 0960-0760.

Abstract | Links:

Maltais R, Trottier A, Roy J, Ayan D, Bertrand N, Poirier D

Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments.

Journal Article

J Steroid Biochem Mol Biol, 178 , pp. 167-176, 2018, ISSN: 0960-0760.

Abstract | Links:

Dutour R, Maltais R, Perreault M, Roy J, Poirier D

Parallel Solid-Phase Synthesis Using a New Diethylsilylacetylenic Linker and Leading to Mestranol Derivatives with Potent Antiproliferative Activities on Multiple Cancer Cell Lines.

Journal Article

Anticancer Agents Med Chem, 2018, ISSN: 1871-5206.

Abstract | Links:

Perreault M, Maltais R, Kenmogne LC, Letourneau D, LeHoux JG, Gobeil S, Poirier D

Implication of STARD5 and cholesterol homeostasis disturbance in the endoplasmic reticulum stress-related response induced by pro-apoptotic aminosteroid RM-133.

Journal Article

Pharmacol Res, 128 , pp. 52-60, 2018, ISSN: 1043-6618.

Abstract | Links:

Djigoue GB, Poirier D

Introducing molecular diversity at the C20-position of pregnenolone by the formation of spiro-2-morpholinones

Journal Article

Curr Org Synth, 15 (4), pp. 541-551, 2018, ISSN: 1570-1794.

| Links:

202 entries « 1 of 41 »

Active projects

  • Centre de recherche en endocrinologie, métabolisme et inflammation, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2023-04-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Démonstration de l'efficacité du premier inhibiteur irréversible et sélectif de la 17beta-HSD1 pour le traitement des cancers du sein sensibles aux estrogènes, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2020-03-31
  • Développement d’un traitement sélectif de l’endométriose : Étude du potentiel du premier inhibiteur irréversible de la 17beta-HSD1 chez le primate, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2017-04-01 to 2019-09-30

Recently finished projects

  • An outstanding accumulation of a 17-beta-hydroxysteroid dehydrogenase type 3 (17b-HSD3) inhibitor in prostate tumor open the door to a specific treatment and imaging of prostate cancer using a radiolabeled 17b-HSD3 inhibitor., Subvention, Cancer de la prostate Canada, Subventions d'équipe Movember (Movember Discovery Grants), from 2014-07-01 to 2016-06-30
  • Développement accéléré d'un inhibiteur de la 17B-HSD10 contre la maladie d'Alzheimer, Partenariat, MITACS Inc., Accélération Québec (MITACS/MESI), from 2016-05-09 to 2017-07-05
  • Evaluation d'une nouvelle famille d'aggravateurs du stress du réticulum endoplasmique pour traiter le cancer du pancréas, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement: cibler les cancers les plus mortels, from 2016-03-01 to 2017-02-28
  • Nouvelle approche thérapeutique pour la maladie d'Alzheimer; un inhibiteur de la 17ß-HSD10 pour moduler trois voies de signalisation., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2017-09-30
  • Optimisation du potentiel thérapeutique de dérivés aminostéroïdes contre le cancer de l'ovaire, Subvention, Instituts de recherche en santé du Canada, Programme de démonstration des principes (PDP), from 2016-04-01 to 2017-03-31
  • Soutien pour achat d'enzymes., Subvention, Fondation du CHU de Québec, from 2017-02-06 to 2017-03-31
  • Synthèse d'analogues du PBRM, un inhibiteur irréversible de la 17B-HSD1, pour traiter deux maladies estrogéno-dépendantes, Partenariat, MITACS Inc., Accélération Québec (MITACS/FQRNT), from 2015-07-01 to 2016-08-31
  • Utilisation de dendrimères fonctionnalisés pour augmenter la solubilité aqueuse et la sélectivité des médicaments: préparation, caractérisation et évaluation biologique., Subvention, Fonds de recherche du Québec - Nature et technologies, Projet de recherche en équipe, from 2014-04-01 to 2017-03-31
Data provided by the Université Laval research projects registery